|
|
|
Insider
Information: |
Aselage Steve |
Relationship: |
Director |
City: |
Fremont |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
5 |
|
Direct
Shares |
293,421 |
|
Indirect Shares
|
19,500 |
|
|
Direct
Value |
$6,853,083 |
|
|
Indirect Value
|
$132,600 |
|
|
Total
Shares |
312,921 |
|
|
Total
Value |
$6,985,683 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
4
|
5
|
Stock
price went up :
|
0
|
3
|
Stock
price went down : |
4
|
2
|
|
|
|
Gain/Loss Ratio : |
-4.0
|
1.5
|
Percentage
Gain/Loss : |
-31.1%
|
62.9%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Cti Biopharma Corporation |
CTIC |
EVP, Global Commercial... |
2005-06-30 |
24,133 |
2004-08-03 |
0 |
Premium* |
|
Biomarin Pharmaceutical Inc |
BMRN |
EVP, Chief Business Of... |
2012-07-02 |
59,030 |
2006-04-28 |
0 |
Premium* |
|
Travere Therapeutics, Inc |
TVTX |
Director |
2022-05-11 |
146,919 |
2021-11-05 |
19,500 |
Premium* |
|
Acer Therapeutics Inc |
ACER |
Director |
2023-11-17 |
0 |
2017-09-19 |
0 |
Premium* |
|
Biocryst Pharmaceuticals Inc |
BCRX |
Director |
2023-06-13 |
63,339 |
2019-03-12 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
169 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 4 of 7
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
BCRX |
Biocryst Pharmaceuticals ... |
Director |
|
2022-05-31 |
4 |
A |
$9.31 |
$5,297 |
D/D |
569 |
33,728 |
0 |
- |
|
TVTX |
Travere Therapeutics, Inc |
Director |
|
2021-02-02 |
4 |
OE |
$10.09 |
$252,250 |
D/D |
25,000 |
221,667 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
SVP, Global Commercial Dev. |
|
2008-04-30 |
4 |
B |
$10.37 |
$15,825 |
D/D |
1,526 |
33,560 |
2.74 |
- |
|
BCRX |
Biocryst Pharmaceuticals ... |
Director |
|
2021-02-26 |
4 |
A |
$10.78 |
$9,993 |
D/D |
927 |
31,496 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
SVP, Global Commercial Dev |
|
2009-04-30 |
4 |
A |
$10.93 |
$16,560 |
D/D |
1,515 |
33,916 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Business Officer |
|
2009-10-31 |
5 |
B |
$11.60 |
$4,119 |
D/D |
355 |
51,271 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Business Officer |
|
2010-04-30 |
4 |
A |
$11.64 |
$17,827 |
D/D |
1,532 |
21,387 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Business Officer |
|
2010-10-29 |
4 |
A |
$11.64 |
$3,421 |
D/D |
294 |
37,881 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Business Officer |
|
2011-04-29 |
4 |
A |
$11.64 |
$18,583 |
D/D |
1,597 |
31,478 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Business Officer |
|
2010-09-08 |
4 |
OE |
$11.74 |
$410,900 |
D/D |
35,000 |
72,587 |
0 |
- |
|
ACER |
Acer Therapeutics Inc |
Director |
|
2017-12-14 |
4 |
B |
$12.00 |
$24,000 |
D/D |
2,000 |
13,905 |
2.39 |
- |
|
BCRX |
Biocryst Pharmaceuticals ... |
Director |
|
2021-11-30 |
4 |
A |
$12.06 |
$4,993 |
D/D |
414 |
32,858 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Business Officer |
|
2011-10-31 |
5 |
B |
$13.23 |
$2,658 |
D/D |
201 |
46,679 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
SVP, Global Commercial Dev |
|
2008-10-31 |
5 |
B |
$13.35 |
$16,506 |
D/D |
1,236 |
32,401 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Business Officer |
|
2010-11-17 |
4 |
OE |
$14.39 |
$7,195 |
D/D |
500 |
30,381 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Business Officer |
|
2010-11-18 |
4 |
OE |
$14.39 |
$451,486 |
D/D |
31,375 |
61,756 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Business Officer |
|
2011-10-28 |
4 |
OE |
$14.39 |
$242,831 |
D/D |
16,875 |
63,353 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Business Officer |
|
2012-05-11 |
4 |
OE |
$14.39 |
$324,480 |
D/D |
21,530 |
68,340 |
0 |
- |
|
TVTX |
Travere Therapeutics, Inc |
Director |
|
2020-05-14 |
4 |
AS |
$15.09 |
$46,206 |
D/D |
(3,062) |
245,732 |
0 |
% |
|
TVTX |
Travere Therapeutics, Inc |
Director |
|
2020-03-05 |
4 |
S |
$15.36 |
$66,939 |
D/D |
(4,359) |
256,357 |
0 |
% |
|
BCRX |
Biocryst Pharmaceuticals ... |
Director |
|
2021-05-28 |
4 |
A |
$15.77 |
$9,998 |
D/D |
634 |
32,130 |
0 |
- |
|
TVTX |
Travere Therapeutics, Inc |
Director |
|
2020-05-05 |
4 |
AS |
$15.88 |
$39,700 |
D/D |
(2,500) |
253,857 |
0 |
% |
|
BCRX |
Biocryst Pharmaceuticals ... |
Director |
|
2021-08-31 |
4 |
A |
$15.92 |
$4,999 |
D/D |
314 |
32,444 |
0 |
- |
|
TVTX |
Travere Therapeutics, Inc |
Director |
|
2021-03-17 |
4 |
OE |
$16.23 |
$162,300 |
D/D |
10,000 |
206,667 |
0 |
- |
|
TVTX |
Travere Therapeutics, Inc |
Director |
|
2021-04-16 |
4 |
OE |
$16.23 |
$162,300 |
D/D |
10,000 |
198,940 |
0 |
- |
|
169 Records found
|
|
Page 4 of 7 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|